BioMotiv

Award-Winning Model in Impact Investing

BioMotiv is a mission-aligned partner of Harrington Discovery Institute, established under The Harrington Project for Discovery & Development in 2012. BioMotiv aligns drug development expertise, capital, and pharmaceutical partners to accelerate discoveries into medicines.

BioMotiv provides:

• Pharmaceutical expertise — The company's leadership and portfolio teams are well-versed in translational science and have supported early-stage discovery programs into clinical development. 
• Capital — BioMotiv provides the initial investment and actively secures additional funds to advance its portfolio companies.
• Industry partnerships — The company has established strategic partnerships with Bristol-Myers Squibb Company and Charles River Laboratories as well as investments from Takeda, Biogen, and Arix Bioscience to leverage a wide set of capabilities.
• Efficient operating platform — BioMotiv provides an operating platform that offers business development, legal, financial, and operational expertise for drug development.

In 2021, the Journal of Commercial Biotechnology recognized BioMotiv as one of the top two innovative organizations in their External Innovators category.